We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

38 hedge funds and large institutions have $4.34M invested in Navidea Biopharmaceuticals Inc. in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

7% more call options, than puts

Call options by funds: $397K | Put options by funds: $372K

7% less funds holding

Funds holding: 41 → 38 (-3)

28% less capital invested

Capital invested by funds: $6.01M → $4.34M (-$1.68M)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
38
Holders Change
-3
Holders Change %
-7.32%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
9
Closed
8
Calls
$397K
Puts
$372K
Net Calls
+$25K
Net Calls Change
-$99K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.19M
2
BCM
Bridgeway Capital Management
Texas
+$251K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$147K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$130K
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$120K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$548K
2
FIA
FNY Investment Advisers
New York
-$413K
3
OFG
OTA Financial Group
New York
-$258K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$168K
5
Two Sigma Investments
Two Sigma Investments
New York
-$79.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
LFG
26
LifePlan Financial Group
Ohio
$4K – – –
JCM
27
Jacobi Capital Management
Pennsylvania
$3K – – –
SIS
28
Sound Income Strategies
Florida
$2K – – –
HPC
29
HM Payson & Co
Maine
$1K – – –
Osaic Holdings
30
Osaic Holdings
Arizona
$1K – – –
PA
31
Parallel Advisors
California
$1K – – –
ASN
32
Advisory Services Network
Georgia
$1K +$897 +250 New
KFS
33
Kelly Financial Services
Massachusetts
$135 – – –
FIA
34
FNY Investment Advisers
New York
– -$413K -105,000 Closed
OFG
35
OTA Financial Group
New York
– -$258K -65,600 Closed
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
– -$168K -46,921 Closed
VF
37
Virtu Financial
New York
– -$69K -17,586 Closed
Wolverine Trading
38
Wolverine Trading
Illinois
– -$56.7K -15,805 Closed
OSAM
39
O'Shaughnessy Asset Management
Connecticut
– +$183 +51 New
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
– +$574 +160 New
1
2

NAVB Hedge Fund Activity: Q3 2020 in Review

38 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2020, worth a combined $4.34M — down 28% from $6.01M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of NAVB and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 10 added.

The largest buyer was Vanguard Group, adding an estimated $1.19M. The largest seller was Renaissance Technologies, cutting an estimated $548K.

  • 38 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2020, down from 41 in Q2 2020.
  • Funds reported $4.34M of Navidea Biopharmaceuticals Inc. stock for Q3 2020, down 28% quarter-over-quarter.
  • 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2020 and 8 closed out, a net change of -3 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2020 was Vanguard Group, an estimated $1.19M added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q3 2020 was Renaissance Technologies, an estimated $548K sold.

Based on aggregated 13F filings for Q3 2020.